Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Survey: Avastin and recurrent ovarian cancer

We understand that the manufacturer of AVASTIN, Hoffman-LaRoche, will be applying for approval from Health Canada in the near future for the use of AVASTIN for women with recurrent ovarian cancer. AVASTIN has been used by some doctors to treat recurrent ovarian cancer. Women who have used AVASTIN have received it through a clinical trial or paid for it themselves.  Bevacizumab, known by its brand name, AVASTIN deprives tumours of the blood supply they need helping the tumour to wither away. Information about AVASTIN and related side effects can be found on line at http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancer-drugs/bevacizumab


As a component of the approval process, Ovarian Cancer Canada has the opportunity to provide a patient submission which outlines the views of patients and their caregivers. We are collecting the views of women living with ovarian cancer and their caregivers through a survey. We are especially interested in hearing from women (or caregivers) who have taken AVASTIN or who have wanted to take AVASTIN. Those eligible to fill out the surveys are:



1) women who have been diagnosed with ovarian cancer between 2000-2013 and treated with chemotherapy;  

2) women who have had a recurrence of ovarian cancer and treated with additional chemotherapy;

3) women who have taken AVASTIN as a treatment for their ovarian cancer;

4) caregivers of women who have (or had) ovarian cancer.





The survey for women living with ovarian cancer can be found at http://www.surveymonkey.com/s/ovcatreatment


The survey for caregivers can be found at http://www.surveymonkey.com/s/ovcatreatmentcare


If you have any questions, please contact Kelly Grover at kgrover@ovariancanada.org


Complementary and Alternative Therapies


Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada

%d bloggers like this: